BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

377 related articles for article (PubMed ID: 30628663)

  • 1. miR‑505 inhibits cell growth and EMT by targeting MAP3K3 through the AKT‑NFκB pathway in NSCLC cells.
    Tang H; Lv W; Sun W; Bi Q; Hao Y
    Int J Mol Med; 2019 Mar; 43(3):1203-1216. PubMed ID: 30628663
    [TBL] [Abstract][Full Text] [Related]  

  • 2. miR‑379 inhibits cell proliferation and epithelial‑mesenchymal transition by targeting CHUK through the NF‑κB pathway in non‑small cell lung cancer.
    Liu B; Wang Z; Cheng S; Du L; Yin Y; Yang Z; Zhou J
    Mol Med Rep; 2019 Aug; 20(2):1418-1428. PubMed ID: 31173238
    [TBL] [Abstract][Full Text] [Related]  

  • 3. MicroRNA-92a promotes epithelial-mesenchymal transition through activation of PTEN/PI3K/AKT signaling pathway in non-small cell lung cancer metastasis.
    Lu C; Shan Z; Hong J; Yang L
    Int J Oncol; 2017 Jul; 51(1):235-244. PubMed ID: 28534966
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Tumor-suppressive effects of microRNA-181d-5p on non-small-cell lung cancer through the CDKN3-mediated Akt signaling pathway in vivo and in vitro.
    Gao LM; Zheng Y; Wang P; Zheng L; Zhang WL; Di Y; Chen LL; Yin XB; Tian Q; Shi SS; Xu SF
    Am J Physiol Lung Cell Mol Physiol; 2019 May; 316(5):L918-L933. PubMed ID: 30628487
    [TBL] [Abstract][Full Text] [Related]  

  • 5. MiroRNA-188 Acts as Tumor Suppressor in Non-Small-Cell Lung Cancer by Targeting MAP3K3.
    Zhao L; Ni X; Zhao L; Zhang Y; Jin D; Yin W; Wang D; Zhang W
    Mol Pharm; 2018 Apr; 15(4):1682-1689. PubMed ID: 29528232
    [TBL] [Abstract][Full Text] [Related]  

  • 6. MiR-182 inhibits the epithelial to mesenchymal transition and metastasis of lung cancer cells by targeting the Met gene.
    Li Y; Zhang H; Li Y; Zhao C; Fan Y; Liu J; Li X; Liu H; Chen J
    Mol Carcinog; 2018 Jan; 57(1):125-136. PubMed ID: 28940757
    [TBL] [Abstract][Full Text] [Related]  

  • 7. LncRNA MALAT1 promotes migration and invasion of non-small-cell lung cancer by targeting miR-206 and activating Akt/mTOR signaling.
    Tang Y; Xiao G; Chen Y; Deng Y
    Anticancer Drugs; 2018 Sep; 29(8):725-735. PubMed ID: 29916897
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Sirtuin 7 promotes non‑small cell lung cancer progression by facilitating G1/S phase and epithelial‑mesenchymal transition and activating AKT and ERK1/2 signaling.
    Zhao Y; Ye X; Chen R; Gao Q; Zhao D; Ling C; Qian Y; Xu C; Tao M; Xie Y
    Oncol Rep; 2020 Sep; 44(3):959-972. PubMed ID: 32705247
    [TBL] [Abstract][Full Text] [Related]  

  • 9. miR-99a suppresses the metastasis of human non-small cell lung cancer cells by targeting AKT1 signaling pathway.
    Yu SH; Zhang CL; Dong FS; Zhang YM
    J Cell Biochem; 2015 Feb; 116(2):268-76. PubMed ID: 25187230
    [TBL] [Abstract][Full Text] [Related]  

  • 10. MiR-770 inhibits tumorigenesis and EMT by targeting JMJD6 and regulating WNT/β-catenin pathway in non-small cell lung cancer.
    Zhang Z; Yang Y; Zhang X
    Life Sci; 2017 Nov; 188():163-171. PubMed ID: 28882645
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effect of microRNA-135a on Cell Proliferation, Migration, Invasion, Apoptosis and Tumor Angiogenesis Through the IGF-1/PI3K/Akt Signaling Pathway in Non-Small Cell Lung Cancer.
    Zhou Y; Li S; Li J; Wang D; Li Q
    Cell Physiol Biochem; 2017; 42(4):1431-1446. PubMed ID: 28715819
    [TBL] [Abstract][Full Text] [Related]  

  • 12. miR‑593 inhibits proliferation and invasion and promotes apoptosis in non‑small cell lung cancer cells by targeting SLUG‑associated signaling pathways.
    Wei F; Wang M; Li Z; Wang Y; Zhou Y
    Mol Med Rep; 2019 Dec; 20(6):5172-5182. PubMed ID: 31661137
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Inactivation of M2 AChR/NF-κB signaling axis reverses epithelial-mesenchymal transition (EMT) and suppresses migration and invasion in non-small cell lung cancer (NSCLC).
    Zhao Q; Yue J; Zhang C; Gu X; Chen H; Xu L
    Oncotarget; 2015 Oct; 6(30):29335-46. PubMed ID: 26336823
    [TBL] [Abstract][Full Text] [Related]  

  • 14. MAP3K3 expression in tumor cells and tumor-infiltrating lymphocytes is correlated with favorable patient survival in lung cancer.
    He Y; Wang L; Liu W; Zhong J; Bai S; Wang Z; Thomas DG; Lin J; Reddy RM; Ramnath N; Carrott PW; Lynch WR; Orringer MB; Chang AC; Beer DG; Chen G
    Sci Rep; 2015 Jun; 5():11471. PubMed ID: 26088427
    [TBL] [Abstract][Full Text] [Related]  

  • 15. MiR-138 inhibits cell proliferation and reverses epithelial-mesenchymal transition in non-small cell lung cancer cells by targeting GIT1 and SEMA4C.
    Li J; Wang Q; Wen R; Liang J; Zhong X; Yang W; Su D; Tang J
    J Cell Mol Med; 2015 Dec; 19(12):2793-805. PubMed ID: 26283050
    [TBL] [Abstract][Full Text] [Related]  

  • 16. MicroRNA-422a functions as a tumor suppressor in non-small cell lung cancer through SULF2-mediated TGF-β/SMAD signaling pathway.
    Li WQ; Zhang JP; Wang YY; Li XZ; Sun L
    Cell Cycle; 2019 Aug; 18(15):1727-1744. PubMed ID: 31204561
    [TBL] [Abstract][Full Text] [Related]  

  • 17. B-Myb Mediates Proliferation and Migration of Non-Small-Cell Lung Cancer via Suppressing IGFBP3.
    Fan X; Wang Y; Jiang T; Cai W; Jin Y; Niu Y; Zhu H; Bu Y
    Int J Mol Sci; 2018 May; 19(5):. PubMed ID: 29772705
    [TBL] [Abstract][Full Text] [Related]  

  • 18. MicroRNA‑103 modulates tumor progression by targeting KLF7 in non‑small cell lung cancer.
    Li K; Yuan C
    Int J Mol Med; 2020 Sep; 46(3):1013-1028. PubMed ID: 32582959
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Knockdown of LncRNA-XIST Suppresses Proliferation and TGF-β1-Induced EMT in NSCLC Through the Notch-1 Pathway by Regulation of miR-137.
    Wang X; Zhang G; Cheng Z; Dai L; Jia L; Jing X; Wang H; Zhang R; Liu M; Jiang T; Yang Y; Yang M
    Genet Test Mol Biomarkers; 2018 Jun; 22(6):333-342. PubMed ID: 29812958
    [TBL] [Abstract][Full Text] [Related]  

  • 20. LncRNA BC200 regulates the cell proliferation and cisplatin resistance in non-small cell lung cancer via PI3K/AKT pathway.
    Gao BB; Wang SX
    Eur Rev Med Pharmacol Sci; 2019 Feb; 23(3):1093-1101. PubMed ID: 30779077
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.